Dr. Lars Birgerson: Research and development of cancer drugs is an inexhaustible driving force.

Introduction: The past two decades have been almost the golden age of the development of oncology, with the doubling of research results.
annual meeting of the European Society of Oncology (ESMO), Arnaud Pharmaceuticals released its Phase 1b clinical data for an AN0025 (EP4 antagonist) as a new complementary therapy for the treatment of localized rectal cancer.
in the study, nearly 40% of patients did not require surgery or postoperative specimens to achieve pathological complete remission. "This finding is very encouraging and we plan to launch a randomized clinical trial of AN0025 plus chemotherapy immediately," said Dr. Lars Birgerson, Chief Development Officer of
Arno Pharmaceuticals and President and CEO of Arnold USA, at ESMO.
we believe that AN0025 has a unique leading position in the research track of EP4, which combines a variety of treatments, including joint immunocheckpoint inhibitors, to treat a wide range of solid tumors, and will have great application prospects.
", "The author had the privilege of conducting an exclusive interview with Dr. Birgerson to learn about Arnold Pharma's product development strategy and the secrets of rapid growth.
Arnold Pharmaceuticals transformed its 2016 innovation into an innovative drug focused on oncology therapy, with its headquarters in Hangzhou and the U.S. headquartered in North Brunswick, New Jersey.
August 2018, Dr. Birgerson joined Arnold Pharma as Chief Development Officer and President and CEO of Arnold USA. Prior to
, Dr. Birgerson has worked as an executive at internationally renowned pharmaceutical companies such as BMS, Roche and Genentech, and has more than 25 years of experience in clinical development and business experience in pharmaceuticals worldwide.
Golden Age" the past two decades have been almost the golden age of oncology, with the growth of research doubling.
in 2018, about 849 cancer projects are under study, and tumors are now the largest field of indications in medicine.
," Dr. Birgerson said.
we can see the rapid development of cancer treatment drugs in China from Arnold Pharmaceuticals.
Arnold Pharmaceuticals transformation has been in just over 3 years, has formed a globally competitive product pipeline, including three clinical phase products, including the FDA Fast Track Qualified AN2025 (Buparlisib) project, is about to enter the global multi-center clinical phase 3; The injectable tumor virus AN1004 (Pelareorep) project is about to enter Phase 3 of the global multi-center clinical phase, and the global potential first-in-class tumor immuno-AN0025 (EP4 antagonasist) project has completed Phase 1b in Europe and the United States.
, there are more than a dozen preclinical candidate compounds represented by AN3005 (STING agonisant that can be administered intravenously) and AN4005 (oral PD-L1).
"Now cancer drug research and development is in full swing, the evolution of the market is more and more favorable to us, we still have a very large room for growth."
more important, through our continued development of cancer drugs, there is hope for patients whose medical needs are not met.
," Dr. Birgerson said.
innovation is the inexhaustible driving force of research and development in the past two decades, with the continuous breakthrough in the field of life science research, anti-cancer drug research and development has also undergone tremendous changes.
about the development of anti-cancer drugs, Dr Birgerson said: "Herceptin and lytoxiate were breakthrough products 20 years ago, and it wasn't until many years later that they faced new competition.
today, the emergence of a product may still be breakthrough, but the product replacement is faster, similar products will soon appear new products.
" the field of cancer treatment is the gold market, but the competition is cruel, to really achieve rapid development, innovation is imperative. Dr
Dr Birgerson said: "A cancer drug research and development company, with clinical products alone, is not enough, it has to have differentiated products in order to be successful in the future market."
in information technology, information and data processing innovation is also very important.
we have to create shorter product development cycles and bring products to market faster to make up for the short product life cycle.
in addition, we have to innovate in the handling of regulatory issues, clinical research and development, and cost-paying models to better bring our products to market.
" focus on unmet clinical needs, speed up the listing of original research for enterprises, must find the most benefit from the product of the target group, clear consumer groups, in order to be targeted.
Arnold Pharmaceuticals is developing the second-line treatment drug for head and neck cancer, AN2025 (Buparlisib /PI3K inhibitor) as a starting point and is expected to become the first product to be marketed by Arnold Pharmaceuticals.
"Immune checkpoint inhibitors and chemotherapy are becoming a first-line treatment for head and neck cancer, and although this is a breakthrough treatment, about 80% of patients still develop further, with a huge unmet clinical need in the field of second-line treatment of head and neck cancer."
" Dr. Birgerson introduced the challenges and opportunities of the current treatment of head and neck cancer.
animal data show that AN2025 has great potential for tumor treatment simply for PD-1 drug non-response/PD-1 tolerance, or with failed chemotherapy.
AN2025 is expected to fill the gap in second-line treatment for patients with pD-1 drug head and neck cancer.
previously, AN2025 has been qualified for the FDA Fast Track, is about to enter the global multi-center clinical Phase III. Dr
Birgerson said: "Arnold is preparing for the PHASE III clinical trial of AN2025, which aims to recruit nearly 500 patients in more than 120 locations around the world.
"it is understood that the FDA has agreed that Arnold Pharmaceuticals will declare the NDA in advance when the results of the ORR mid-term analysis reach pre-set statistical significance, and will expedite the review, which means that AN2025 is expected to be approved for future listing time significantly ahead of schedule."
"potential unit" in cancer treatment, the most mentioned word in an interview with Dr. Birgerson, shows his love of the job and research and development.
Dr. Birgerson has a wealth of experience, he holds both M.D. and Ph.D. degrees, completed the study of obstetrics and gynecology, general surgery, gynaecological oncology and urology in The University of Uzansala, Sweden, before leaving academia to join the International Pharmaceutical Company as an executive, accumulated more than 25 years of global clinical development and business experience in pharmaceuticals. "Arnold Pharmaceuticals is a very promising company in the cancer treatment field of the future," said Dr.
, referring to why he chose to join a start-up biopharmaceutical company such as Arnold Pharmaceuticals.
first, Arnault Pharmaceuticals is a global pharmaceutical company based in China, the company's vision is to become a world-class biopharmaceutical company, positioned to do global sales of innovative drugs, which has a great appeal to me;
" interview, Dr. Birgerson described to the author the vision of Arno Pharma's product development and company development for the next five years, saying: "In five years, Arnold Pharmaceuticals is expected to become a world-renowned biotech public company, and Arnold's products will enter the world's major pharmaceutical markets."
to this end, we must speed up the clinical phase of product development, as soon as possible to complete its registration and approval in major global markets, pre-clinical projects to the clinical development stage, while expanding commercial cooperation, further enhance the product pipeline, to ensure that the company has both listed and sold products, but also in clinical development of products.
"For the development of cancer drugs and the future development of Arnold's medicine, Dr. Birgerson firmly believes that the future is bright." "I am very honored to be a member of Arnold Pharmaceuticals and to realize this vision for myself,"
said.
"